

Supplementary Table 4. Sensitivity analysis of Liang score to predict HCC in patients who never received antiviral treatment and patients who received antiviral treatment, censored at the start date of the first antiviral treatment in the training cohort

	Patients without NA treatment	Patients with NA treatment
Sensitivity	81.82 (59.72–94.81)	84.38 (73.14–92.24)
Specificity	61.11 (60.01–62.21)	47.33 (45.98–48.68)
PPV	0.60 (0.50–0.74)	1.89 (1.70–2.10)
NPV	99.91 (99.79–99.96)	99.61 (99.30–99.78)
No of HCC predicted	18/22 (81.82)	54/64 (84.38)
No of patients in the low-risk group	4,659/7,639 (60.99)	2,532/5,393 (46.95)

Values are presented as percentage (95% confidence interval) or number (%).

HCC, hepatocellular carcinoma; NA, nucleos(t)ide analogues; PPV, positive predictive value; NPV, negative predictive value.